8-K filing — DataMeds AI, Inc. (MEDS)
Filed: 2026-11-17 AccNo: 0001493152-26-052897 Size: 237 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
DataMEDS AI, Inc. reported the first commercial sale of compounded peptides by its Corexa Pharmacy unit, following compliance with recent HHS Enforcement Discretion Policy guidelines.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-11-17 AccNo: 0001493152-26-052897 Size: 237 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
DataMEDS AI, Inc. announced its financial results for the third quarter ended September 30, 2026, reporting a net operating profit of $10.535 million compared to a net operating loss of $34.318 million in the same period last year.
FDA requires new NAION eye warning on all GLP-1 drugs, citing potential increased risk.
Datavault AI ousts CEO Nathaniel Bradley amid scrutiny over a $150M Bitcoin deal restatement and going-concern risks. Get the latest.